BRIDGenomics helps clinical organizations develop and commercialize genomic testing to maximize their return on investment. Their experienced team can reduce the time to assay commercialization by 75% and help grow revenue quickly. They have successfully commercialized next-generation sequencing assays in under 3 months for various clients. BRIDGenomics leverages over 25 years of experience in molecular testing, next-generation sequencing, and clinical diagnostics to provide consulting, partnering, and staffing services to support clients throughout the entire assay commercialization process.
2. Maximize Your Return on Investment
BRIDGenomics helps clinical organizations develop and
commercialize genomic testing and maximize ROI.
Our highly experienced team can reduce your time to assay
commercialization by 75% and help you quickly grow revenue.
We’ve done this before and we can do it for you.
Quest Diagnostics
LabPMM Invivoscribe
Cancer Genetics Inc
BioGx
Geneuity
MPLN
3. Assay Commercialization
Typical NGS Assay Commercialization Timeline: 9 -18 months
Typical NGS Assay Commercialization Cost: $500k - $750k
These estimates exclude the cost of equipment
We routinely commercialize NGS-based LDTs in less than 3 months
BRIDGenomics average timeline includes: build out and staffing of lab space, as well as
commercialization of testing including state inspection/accreditation in under 90 days.
4. Experience Empowers
Our Team’s Selected Publications
This is why we routinely commercialize NGS-based LDTs in less than 3 months
Products Developed and Commercialized Projects supporting multiple sectors
Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. 2015.
PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419
A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-
Experienced Patients. 2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334
CLSI. Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition.
CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.
5. Depend on our Deep Domain Knowledge
More than 25 years of experience
▪ System, Product, and Assay development and validation
▪ High-Complexity Molecular Testing
▪ Emerging Technology Market Assessment
▪ Implementation of New Technologies
▪ PI on Clinical Studies for Pharma
▪ Invited Speaker
▪ Significant Patent Portfolio
More than 15 years of global industry experience in
molecular testing and NGS
▪ System, Product, and Assay Launch
▪ Wet bench and Bioinformatic Experienced
▪ SEAM Management Certified
▪ VOC, KOL and Market Development
▪ Focus Groups/Advisory Board Leader
▪ Significant Biomarker and Content Expertise
More than 15 years of clinical diagnostics experience
▪ Assay development, validation, & commercialization
▪ High-Complexity Molecular Testing
▪ Emerging Technology Market Assessment
▪ Implementation of New Technologies in Clinical Diagnostics
▪ Clinical Trials for Pharma and Device Manufacturers
▪ Genomics program development and pipeline strategies
▪ Strategic development and M & A’s
Jamie Platt, PhD, MB(ASCP)
CEO/Founder
Shawn Clairmont, MBA
Chief Operating Officer
Martin Siaw, PhD, MB(ASCP)
VP of Science & Innovation
Invited Speakers at the Liquid Biopsy Summit,
NextGen Dx Summit, Molecular Medicine TriConference….
6. Consulting & Partnering Services
Market
Strategy and
Development
Portfolio
Pipeline
Development
Genomics
Next Generation
Sequencing
Technology
Emerging
Technology
Development
LDT
Development
Process
Locum Tenens
Staffing and
Recruiting
Focus Group
&
Advisory Board
Informatics
8. Examples of Completed Projects
Global Business Development
Build out (de novo)
Transition (low- to high-complexity)
Assay Pipeline Strategy Development
Validation Guidance
NGS Technical Expertise
Workflow and Automation
Customization
Regulatory
CAP accreditation
CLIA certification
NYS CLEP
ISO 15189
ISO 13485
California DFS
COLA
Pharma + Service Provider
Device Co. + Technology Co.
Lab + Tools Provider
Service Provider + Software Co.
Lab + Lab
Strategic Marketing
Market Assessment
Content Marketing
Focus Groups
Advisory Boards
White Papers
Laboratory
Sales and Marketing
9. More than Information… Solutions
We’d love to connect with you!
info@BRIDGenomics.com
949-244-2591